The glucose-dependent insulinotropic polypeptide receptor: A novel target for neuroendocrine tumor imaging - First preclinical studies

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 976-982

  Gourni, Eleni ^a   Waser, Beatrice ^c   Clerc, Pascal ^d   Fourmy, Daniel ^d   Reubi, Jean Claude ^c   Maecke, Helmut R ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d Institut de la Santé et de la Recherche Médicale   (France)

Author keywords

Glucose dependent insulinotropic polypeptide receptor (GIPr); Imaging; Neuroendocrine tumors (NETs)

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GALLIUM 68; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; INDIUM 111; LYSINE; NEUROPEPTIDE RECEPTOR; RADIOLIGAND; TETRAXETAN; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; INDIUM; LIGAND; PEPTIDE FRAGMENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ENDOCRINE CELL; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR AFFINITY; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; HAMSTER; HUMAN; KIDNEY; METABOLISM; NUDE MOUSE; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CRICETINAE; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; KIDNEY; LIGANDS; MICE; MICE, NUDE; NEUROENDOCRINE TUMORS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, GASTROINTESTINAL HORMONE; TISSUE DISTRIBUTION;

EID: 84903129231     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.133744     Document Type: Article

References (32)

1. Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S11-S30.
2. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods. 2009;48:161-177.
3. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas - a prospective study. Ann Intern Med. 1996;125:26-34.
4. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [ 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-2423.
5. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastropancreatic (GEP) tumors with the novel radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
6. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
7. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011;52:841-844.
8. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793. (Pubitemid 36612963)
9. Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch. 2007;451 (suppl 1):S47-S50. (Pubitemid 47283376)
10. Körner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743. (Pubitemid 47604973)
11. Reubi JC. Old and new peptide receptor targets in cancer: future directions. Recent Results Cancer Res. 2013;194:567-576.
12. Wild D, Béhé M, Wicki A, et al. [Lys40(Ahx-DTPA- 111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-2033.
13. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagon-like peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-1067.
14. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga- labeled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37:1345-1355.
15. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detections of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29:597-606. (Pubitemid 34439319)
16. Murage EN, Gao H, Bisello A, Ahn JM. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem. 2010;53:6412-6420.
17. Kiesewetter DO, Gao H, Ma Y, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging. 2012;39:463-473.
18. Wild D, Maecke HR, Christ E, Gloor B, Reubi JC. Glucagon-like peptide-1 receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
19. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
20. Waser B, Rehmann R, Sanchez C, Fourmy D, Reubi JC. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors. J Clin Endocrinol Metab. 2012;97:482-488.
21. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of the G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8:179-188.
22. McIntosh CH, Widenmaier S, Kim SJ. Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitam Horm. 2009;80:409-471.
23. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24. (Pubitemid 29505281)
24. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab. 2009;23:443-452.
25. Yaqub T, Tikhonova IG, Lättig J, et al. Identification of the determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand. Mol Pharmacol. 2010;77:547-558.
26. Moon MJ, Kim HY, Kim SG, et al. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors. Mol Cells. 2010;30:149-154.
27. Parthier C, Kleinsschmidt M, Neumann P, et al. Crystal structure of the incretinbound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci USA. 2007;104:13942-13947. (Pubitemid 350003317)
28. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
29. Hinke SA, Manhart S, Pamir N, et al. Identification of bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta. 2001;1547:143-155. (Pubitemid 32441571)
30. Gotthardt M, Eerd-Vismale J, Oyen WJG, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48:596-601. (Pubitemid 47571416)
31. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibitor reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes. 2001;50:1588-1597. (Pubitemid 33639599)
32. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454-1470. (Pubitemid 44560347)